Oral Tolerability of Cysteine-Rich Protein Isolate (Immunocal) in Autism - A Pilot Study

[Guest guest]

Immunocal is very expensive. I suspect many of the results of this

study would also pertain to other brands of less expensive

un-denatured whey.

Alobar

Oral Tolerability of Cysteine-Rich Protein Isolate (Immunocal) in

Autism - A Pilot Study

MONTREAL, Aug. 28 /CNW Telbec/ - Immunotec Inc. (TSX-V: IMM) announced

today the completion of an open-label clinical trial on the use of a

cysteine-rich protein isolate in children with autism. Ten children,

3-15 years of age with a diagnosis of autism or autism spectrum

disorder (ASD), were supplemented with a non-denatured whey protein

isolate (Immunocal®).

Autism symptoms, behavior, side effects, and treatment adherence were

examined, as well as bowel flora. This preliminary study showed the

majority of autistic children were able to consume non-denatured whey

protein isolate (Immunocal®) without adverse effects. Changes in all

behavioural parameters showed positive trends but did not reach

statistical significance because of the small numbers of patients in

this pilot study. The results will provide the basis for a larger

placebo controlled double blind study to test the benefits of using

whey protein isolate in the treatment of autism. (Kern JK, Grannemann

BD, Gutman J, Trivedi MH, Oral Tolerability of Cysteine-Rich Whey

Protein Isolate in Autism - A Pilot Study, Journal of the American

Nutraceutical Association (JANA), Vol. 11, No. 1, 36-41, 2008.)

Recent evidence suggests that many children with autism have low

levels of glutathione in their cells. Non-denatured whey protein can

improve glutathione levels in a variety of diseases and disorders;

however, there are anecdotal reports that children with autism may

have a worsening of behavior, gastrointestinal (GI) disturbance or

related problems after the ingestion of sulfur-rich compounds.

Principle investigator Dr. Janet Kern stated, " We're very optimistic

about these pilot results, it makes us very comfortable to pursue

larger and longer-term studies using this strategy. " Immunotec

President and CEO Jim Northrop is pleased with these initial results.

" Completion of this pilot study will encourage researchers to move on

to the next step of studying the role and benefits of our

cysteine-rich protein (Immunocal) in children with autistic spectrum

disorder. I am proud of Immunotec's commitment to ongoing research and

development that continues to validate the confidence and quality in

our products. "

About Immunocal

Immunocal is a cysteine-rich protein isolate derived from

non-denatured whey protein. Immunocal®/HMS 90®, is a dietary

natural health supplement, developed and marketed worldwide by

Immunotec since 1996. Immunocal®/HMS 90® is a precursor of the

major cellular antioxidant glutathione, an element important in

maintaining a strong immune system.

About Immunotec Inc.

Immunotec is engaged primarily in the development and marketing of

natural health products, dietary supplements, vitamins and personal

care products, many of which are manufactured on its behalf by third

parties. Immunotec's products are distributed and sold in the United

States and Canada through a network marketing system and in other

countries through exclusive distributorship agreements. Immunotec's

investment in this study is another manifestation of its ongoing

commitment to research and development.

www.immunotec.com

http://www.drugs.com/clinical_trials/oral-tolerability-cysteine-rich-protein-iso\

late-immunocal-autism-pilot-study-5376.html